WILLIAM D. QUARLES, JR., District Judge.
Aphena Pharma Solutions-Maryland LLC ("Aphena") sued BioZone Laboratories, Inc. ("BioZone"), BioZone Pharmaceuticals, Inc. ("BioZone Pharmaceuticals"), and Daniel Fisher (collectively "defendants") for contract and fraud claims. Pending are Fisher's motion to dismiss for lack of personal jurisdiction and the defendants' motion to transfer the case to the U.S. District Court for the Northern District of California. Also pending is Aphena's motion for leave to file a surreply to the motion to dismiss. For the following reasons the defendants' motion to transfer will be granted, and Fisher's motion to dismiss for lack of personal jurisdiction will be denied as moot. Leave will not be granted to Aphena to file a surreply.
Aphena, a Delaware LLC formerly known as Celeste Packaging LLC,
BioZone is a California corporation, with its principal place of business in California, founded by Fisher and Dr. Brian Keller in 1989. ECF No. 28-6 ¶ 3. Fisher served as BioZone's president until early 2012. Id. ¶ 4. BioZone Pharmaceuticals, a Nevada corporation with its principal place of business in Florida, agreed to purchase BioZone on June 30, 2011. ECF No. 39-3 at 9, 11. Fisher has lived in California for over 60 years. ECF No. 28-6 ¶ 2. His only physical presence in Maryland was two, two-day vacations. Id. ¶ 21.
The transaction that gave rise to this case began when Russ Haines in New Jersey called Fisher on behalf of Prepak
In negotiating the deal with Aphena, Fisher participated in several phone calls involving Bob Patel, John Allen, and Safee Chaudhri, all in Maryland; Brett Fliegler in New York; Dan Huggins in New Jersey or Tennessee; and Bob Allen in Tennessee. See ECF No. 36 ¶¶ 8, 10. Fisher also sent to and received from Fliegler and Huggins emails on which Patel and Allen were copied. Id. ¶¶ 5, 9. The price quotations for the transactions were sent to Dan Huggins at Prepak in New Jersey. Id. ¶ 4; ECF No. 28-6 ¶ 14. Fisher also communicated directly with Allen about the logistics of the transaction. ECF No. 28-6 ¶ 17-18.
In April 2010, Fisher sent an email directly to Huggins, Patel, Safee, and Taylor about Aphena personnel's upcoming trip to California, arranged by Haines, to meet with Fisher and other BioZone representatives. ECF No. 36 ¶ 7. There were three meetings in California. ECF No. 28-6 ¶¶ 7-9.
During the negotiations, Fisher was informed that Aphena was in Maryland, the agreement was to be delivered to Maryland, only the Maryland facility could manufacture the formulations, and the project would be managed by Aphena's Maryland employees. ECF No. 39-2 ¶ 9. Formulations and related materials provided by BioZone were delivered to Maryland. Id. at 3 ¶ 7.
After the negotiations, all was not well between Aphena and BioZone. In late summer and early fall 2010, Fisher contacted Patel directly about Aphena's failure to pay. ECF No. 28-6 ¶ 20. Aphena alleges that BioZone failed to deliver the formulations on time; when delivered, they did not meet the proper standards. ECF No. 1 ¶¶ 112-19. Aphena also alleges that it was forced to recall all products made from BioZone's work because of deficiencies. Id. ¶ 166.
On March 19, 2012, Aphena sued BioZone, BioZone Pharmaceuticals, and Fisher for (1) breach of contract, (2)-(3) fraud in the inducement, (4)-(5) intentional misrepresentation, (6) negligent misrepresentation, (7) negligent hiring, and (8) unjust enrichment. ECF No. 1. On May 21, 2012, BioZone and BioZone Pharmaceuticals answered. ECF No. 29. The same day, Fisher moved to dismiss for lack of personal jurisdiction.
On July 19, 2012, Aphena moved for leave to file a surreply to Fisher's motion to dismiss. ECF No. 43. On July 30, 2012, Fisher responded, ECF No. 44, and on August 9, 2012, Aphena replied, ECF No. 45.
Aphena seeks leave to file a surreply to Fisher's motion to dismiss because Fisher
Unless otherwise ordered by the Court, a party may not file a surreply. Local Rule 105.2(a) (D.Md. 2012). Leave to file a surreply may be granted when the movant otherwise would be unable to contest matters presented in the opposing party's reply. Khoury v. Meserve, 268 F.Supp.2d 600, 605 (D.Md.2003), aff'd 85 Fed.Appx. 960 (4th Cir.2004).
Fisher had not addressed the legal standard for the dismissal in his motion, but Aphena presented its view of the standard in its opposition. See ECF No. 39 at 27. Fisher then presented his argument on the standard in his reply. ECF No. 40 at 10. As such, the standard was not first raised in the reply. Aphena had the first word on what standard the Court should use. Cf. Khoury, 268 F.Supp.2d at 605. As both sides of the argument have been presented, the motion will be denied.
Aphena asserts that it need make only a prima facie showing of personal jurisdiction. ECF No. 39 at 27. Fisher argues that the summary judgment standard applies under Fed.R.Civ.P. 12(d). ECF No. 40 at 10.
The party asserting the claim has the burden of proving personal jurisdiction. See Combs v. Bakker, 886 F.2d 673, 676 (4th Cir.1989). If jurisdiction turns on disputed facts, the court may resolve the challenge after a separate evidentiary hearing, or may defer ruling until receiving, at trial, evidence relevant to jurisdiction. Id. If the court determines the issue without an evidentiary hearing, and relies only on the complaint, affidavits, and discovery materials, "the plaintiff need only make a prima facie showing of personal jurisdiction." Carefirst of Md., Inc. v. Carefirst Pregnancy Ctrs., Inc., 334 F.3d 390, 396 (4th Cir.2003). In determining whether the prima facie case has been shown, the court "must draw all reasonable inferences arising from the proof, and resolve all factual, disputes in the plaintiff's favor." Mylan Labs., Inc. v. Akzo, N.V., 2 F.3d 56, 60 (4th Cir.1993).
A federal district court may assert specific personal jurisdiction over a non-resident when the exercise of jurisdiction is (1) authorized by the forum state's long-arm statute, and (2) consistent with due process.
Fisher is incorrect that the summary judgment standard is applied under Rule 12(d). Rule 12(d) applies only to motions under 12(b)(6), failure to state a claim, and 12(c), judgment on the pleadings. A motion to dismiss for lack of personal jurisdiction is under Rule 12(b)(2). As the motion is based only on the complaint and affidavits, Aphena need make only a prima facie showing of personal jurisdiction. Carefirst, 334 F.3d at 396.
Fisher argues that his contacts with Maryland are insufficient under the Maryland
Although Maryland's long-arm statute authorizes jurisdiction to the extent allowed by due process, the plaintiff must identify a specific provision authorizing personal jurisdiction.
Aphena asserts that Fisher's contacts with Aphena personnel in Maryland are sufficient to constitute transacting business within the state. ECF No. 39 at 38. Fisher argues that he performed no actions in Maryland, and his communications were directed at persons in other states. See ECF Nos. 28-1 at 11, 40 at 7-9, 13-14.
Under subsection (b)(1), a defendant who "transacts any business" in Maryland is subject to jurisdiction here. Md. Code Ann., Cts. & Jud. Proc. § 6-103(b)(1). Although a defendant need not engage in "commerce or ... transactions for profit,"
None of the cases cited by Aphena requires the exercise of jurisdiction over Fisher. The closest is Jason Pharmaceuticals, Inc. v. Jianas Bros. Packaging Co., 94 Md.App. 425, 617 A.2d 1125 (Md.Ct. Spec.App. 1993). In that case, the defendant initiated contact with the plaintiff and expressed interest in doing business, engaged in negotiations with the plaintiff which was located in Maryland, and sent a down payment to Maryland. Id. at 1129. The Court of Special Appeals held that
The facts in this case are dissimilar. Aphena's parent company initiated contact with Fisher to inquire about purchasing BioZone. See ECF Nos. 28-6 ¶ 5, 36 ¶ 6. Although Aphena personnel from Maryland were involved in the calls between Fisher and Aphena, it appears that the majority of the negotiations were undertaken by individuals outside the state. See ECF No. 28-6 ¶¶ 17-18. Aphena did, however, pay from Maryland, but nothing in the record directly connects Fisher to receipt of the payment. See ECF No. 39-1 at 3 ¶ 9.
This case does not meet the factors that the Court found met subsection (b)(1) in Jason Pharmaceuticals. Cf. Jason Pharms., 617 A.2d at 1129. Further, the other cases on which Aphena relies are distinguishable on similar grounds.
Aphena argues that it sustained injury within Maryland, enabling jurisdiction over Fisher. ECF No. 39 at 39. Fisher asserts that he made no act or omission within the state. ECF Nos. 28-1 at 12, 40 at 15.
Under subsection (b)(3) a defendant who "causes tortious injury in the State by an act or omission in the State" is subject to personal jurisdiction in Maryland. Md. Code Ann., Cts. & Jud. Proc. § 6-103(b)(3). The parties disagree over the requirements of the statute. The Maryland Court of Appeals has not definitively addressed the issue, and the cases of this district vary.
In Dring v. Sullivan, 423 F.Supp.2d 540 (D.Md.2006), the court stated that "[c]ourts have held that ... subsection [(b) (3)] requires that both the tortious injury and the tortious act must have occurred in Maryland." Id. at 546 (collecting cases). Aphena, however, relies on the two Maoz cases.
Subsection (b)(3) contrasts with subsection (b)(4), which permits jurisdiction when there is a tortious injury in or outside the state with an act or omission in or outside the state, when the defendant "does or solicits business, engages in any other persistent course of conduct in the State, or derives substantial revenue from goods, food, services, or manufactured products" in the state. Md.Code Ann, Cts.
Although the results of Fisher's alleged misrepresentations were felt in Maryland, Aphena has not alleged, nor do the affidavits indicate, that Fisher acted in Maryland. The only communications in the record that could give rise to such misrepresentations were phone calls or emails — the types of communications that Zinz held were not acts in Maryland. Zinz, 324 A.2d at 144. Fisher is not subject to jurisdiction under § 6-103(b)(3).
Fisher — arguing that Aphena is not really a Maryland entity — asserts that his activities were not sufficiently directed toward Maryland, and this Court's exercise of jurisdiction would violate due process. ECF No. 40 at 12-13. Aphena asserts that it is based in Maryland, and Fisher had sufficient contacts with the state. ECF No. 39 at 32-37. The due process minimum contacts analysis confirms the lack of jurisdiction under the long-arm statute.
The basis for analyzing personal jurisdiction under due process is "if the defendant has `minimum contacts' with the forum, such that to require the defendant to defend its interests in that state `does not offend traditional notions of fair play and substantial justice.'"
Even drawing all inferences and resolving disputes in favor of Aphena, see Mylan Labs., 2 F.3d at 60, Fisher's contacts do not meet this standard. First, weighing against the required contacts, Prepak, not Fisher, initiated contact. See Johansson Corp. v. Bowness Const. Co., 304 F.Supp.2d 701, 706 (D.Md.2004). Fisher has been to Maryland only twice, and neither trip was connected to the transaction with Aphena. See ECF No. 28-6 ¶ 22.
Fisher was told that the formulations were destined for Maryland, ECF No. 39-4 ¶ 9, and communicated by phone, email, and in person in California with Aphena personnel from Maryland, see Id. ¶ 10, 12; ECF No. 36 ¶ 5, 7-10. Nevertheless, much of Fisher's substantive negotiations were with individuals located outside of Maryland. See ECF No. 36 ¶ 5-8.
Fisher's contact with Maryland is tenuous. The facts do not show that he purposely
Finally, given the unusual nature of this case — concerning jurisdiction over a person relating to transactions between businesses — it seems unlikely that Fisher expected to be haled into court in Maryland for those transactions. See World-Wide Volkswagen, 444 U.S. at 297, 100 S.Ct. 559. Due process does not permit this Court to exercise personal jurisdiction over Fisher. See Carefirst, 334 F.3d at 397. Fisher's motion to dismiss for lack of personal jurisdiction will denied as moot, however, because the defendants' motion to transfer the case to the Northern District of California
The defendants assert that the Court should transfer this case to the Northern District of California because the transfer would be more convenient to the parties and witnesses and serve the interests of justice. ECF No. 35 at 8. Aphena argues that the transfer would not be more convenient or serve the interests of justice, and its choice of forum is entitled to significant weight. ECF No. 39 at 20.
Under 28 U.S.C. § 1404(a),
On a motion to transfer, the Court first asks whether the action could have been brought in the transferee district.
The defendants argue that Aphena's choice of forum is entitled to little weight because its corporate offices are in Tennessee, and the complaint depends on the defendants' acts and omissions in California. ECF No. 35 at 8-9. Aphena argues that Maryland is its home forum, and BioZone worked with Aphena's Maryland employees and delivered products to Maryland for use there. ECF No. 39 at 21.
"Ordinarily, a plaintiff's choice of forum is entitled to substantial weight." Lynch, 237 F.Supp.2d at 617. But, when the chosen forum is not the plaintiff's home or has little connection to the events giving rise to the litigation, less weight is given to the plaintiff's choice. Tse v. Apple Computer, Civ. No. L-05-2149, 2006 WL 2583608, at *2 (D.Md. Aug. 31, 2006).
Apart from its relationship with Prepak, Aphena is currently managed by George Galgano, its general manager, located in Maryland. See ECF Nos. 39-1 at 1-3, 3-2 ¶ 14. A corporation is a resident of the state of its principal place of business — the location where its officers direct activities.
The defendants assert that "[t]he majority of key witnesses are in California," favoring transfer. ECF No. 35 at 10. Aphena argues that the dispute is also dependent on witnesses located in Maryland, and transfer would simply shift inconvenience from the defendants' witnesses to Aphena's. ECF No. 39 at 22-23.
The majority of the defendants' potential witnesses are in California. See ECF No. 35-4. Although several of Aphena's witnesses reside in Maryland, ECF No. 39-1 at 2 ¶¶ 11-13, others likely to be called, such as Huggins, Haines, or Fliegler, reside elsewhere in the eastern United States, see ECF No. 36 ¶¶ 5-7. This favors retaining the case because the "transfer would serve only to shift the balance of inconvenience." Bd. of Trs., Sheet Metal Workers Nat'l Fund v. Baylor Heating & Air Conditioning, 702 F.Supp. 1253, 1258 (E.D.Va.1988).
The defendants argue that California is most convenient because Aphena representatives have previously travelled to California, and key Aphena representatives are in other states and would have to travel regardless. ECF No. 35 at 12. They also argue that BioZone would have to transport its documents. Id. Aphena asserts
That Aphena representatives had previously travelled to California weighs little in the analysis. See FC Invest. Grp. LC v. Lichtenstein, 441 F.Supp.2d 3, 13 (D.D.C. 2006). Further, although BioZone may have to transport documents to Maryland, Aphena would have to do the same to California. On balance, this factor does not favor transfer.
The defendants assert that the interests of justice require transfer because California law will apply to the case and the Northern District of California has personal jurisdiction over Fisher. ECF No. 35 at 13-14. Aphena argues that Maryland law applies to some if not all of its claims, and this Court has personal jurisdiction over Fisher. ECF No. 39 at 25-26.
Familiarity with applicable law is one of the interests of justice factors. See Dicken v. United States, 862 F.Supp. 91, 93-94 (D.Md.1994). The law governing the claims in this case has not been determined. For the tort claims, Maryland applies the law of the jurisdiction "where the last act required to complete the tort occurred." Philip Morris Inc. v. Angeletti, 358 Md. 689, 752 A.2d 200, 231 (2000). Although the defendants argue that any misrepresentations occurred in California, requiring California law, ECF No. 35 at 13, Aphena asserts that it was induced to rely in Maryland, where it also sustained damage, ECF No. 39 at 25. Maryland law is not clear about where the "wrong" occurs in fraud and negligent misrepresentation cases. See CapitalSource Fin. LLC v. B & B Contractors, Inc., Civil No. DKC-04-3739, 2005 WL 1025953, at *10 (D.Md. Apr. 28, 2005).
Similarly, Maryland follows lex loci contractus, applying the law of the jurisdiction where the last act necessary to form a contract was made.
Most importantly, this Court does not have personal jurisdiction over Fisher. See supra Part II.B.2. Fisher's key role in BioZone's negotiations with Aphena indicates that he would be a central figure in any trial in this case. Thus, judicial economy would best be served by Fisher remaining as a defendant and a transfer of the case to the Northern District of California.
For the reasons stated above, Aphena's motion for leave to file a surreply will be denied. The defendants' motion to transfer will be granted. Fisher's motion to dismiss for lack of personal jurisdiction will be denied as moot.